Actinium Pharmaceuticals (STU:7AY1) ROCE % : -64.22% (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Actinium Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Actinium Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2024 was -64.22%.

Actinium Pharmaceuticals ROCE % Historical Data

The historical data trend for Actinium Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals ROCE % Chart

Actinium Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-295.37

-65.33

-38.17

-39.54

-57.83

Actinium Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-68.00	-53.39	-50.18	-62.23	-64.22

Actinium Pharmaceuticals ROCE % Calculation

Actinium Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-47.611	/	( ( (107.797 - 10.033)	+	(74.685 - 7.789) )	/ 2 )
	=	-47.611	/	( (97.764	+	66.896)	/ 2 )
	=	-47.611	/	82.33
	=	-57.83 %

Actinium Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-45.416	/	( ( (83.481 - 9.037)	+	(73.985 - 6.987) )	/ 2 )
	=	-45.416	/	( ( 74.444	+	66.998 )	/ 2 )
	=	-45.416	/	70.721
	=	-64.22 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Actinium Pharmaceuticals (STU:7AY1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Actinium Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinium Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (STU:7AY1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ATNM:USA 7AY1:Germany

Address

100 Park Avenue, 23rd Floor, New York, NY, USA, 10017

Website

https://www.actiniumpharma.com

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Actinium Pharmaceuticals Headlines

No Headlines